
PolyPid (PYPD) Stock Forecast & Price Target
PolyPid (PYPD) Analyst Ratings
Bulls say
PolyPid is a clinical-stage biopharmaceutical company with a proprietary drug delivery technology platform that has the potential to target a wide variety of drugs for localized and extended-release delivery. With a market capitalization of ~$74M and an attractive risk-reward profile, the company has successfully executed on regulatory, partnering, and corporate fronts. Management's focus on both short-term and longer-term opportunities, along with a robust pipeline of candidates, has the potential to drive incremental intellectual property and generate future partnering or internal development opportunities. The company's execution across clinical, regulatory, and commercial pathways supports a positive outlook and potential unlocking of value with approval of their lead product candidate D-PLEX100. While there may be financing risks and a key bottleneck during the approval process is a successful FDA inspection, potential grants and designations, along with a pragmatic go-to-market strategy, provide optimism for a favorable outcome.
Bears say
PolyPid is facing potential risks in the short and medium term, including potential clinical and regulatory setbacks and delays in securing funding. These risks could impede market penetration of their product and lead to potential revenue erosion. The company's current financials and forecasted DCF analysis result in a price target of $9 per share, with potential for revenue contributions in 2036.
This aggregate rating is based on analysts' research of PolyPid and is not a guaranteed prediction by Public.com or investment advice.
PolyPid (PYPD) Analyst Forecast & Price Prediction
Start investing in PolyPid (PYPD)
Order type
Buy in
Order amount
Est. shares
0 shares